A Randomized Open-Label, Phase II Study of Lapatinib-capecitabine or Lapatinib-vinorelbine or Lapatinib/Gemcitabine in Subjects With Her2/Neu Amplified Metastatic Breast Cancer Patients Progression After Taxanes Treatment.

Trial Profile

A Randomized Open-Label, Phase II Study of Lapatinib-capecitabine or Lapatinib-vinorelbine or Lapatinib/Gemcitabine in Subjects With Her2/Neu Amplified Metastatic Breast Cancer Patients Progression After Taxanes Treatment.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2016

At a glance

  • Drugs Lapatinib (Primary) ; Capecitabine; Gemcitabine; Vinorelbine
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 14 Dec 2013 Results presented at the 36th Annual San Antonio Breast Cancer Symposium.
    • 05 Jun 2012 Interim tolerability analysis presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
    • 04 Feb 2011 Planned end date changed from Feb 2011 to Sep 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top